AnHeart Closes $61 Million Round for Precision Oncology Therapies
publication date: Dec 14, 2021
Hangzhou AnHeart Therapeutics closed a $61 million Series B funding to develop precision oncology therapies. The financing was led by new investor Octagon Capital, with participation from Suzhou's Innovent Biologics. In June, Innovent struck a deal with AnHeart to co-develop and commercialize AnHeart’s lead drug candidate, taletrectinib, in greater China. Taletrectinib is a next-generation TKI that targets ROS1 and NTR to treat solid tumors. Cenova, Laurion Capital, and Sage Partners also participated in the B round. More details....
Stock Symbol: (HK: 01801)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.